רווח נקי למניה ב-12 החודשים האחרונים: Generation Bio Co. (GBIO)

The absence of dividends is offset by Generation Bio Co. (GBIO) holding first-mover status in non-viral therapy, which grants the company pricing power. The 12-month earnings per share history serves as a confidence indicator, where the current value equals -9.36. Growth is driven by partnerships with pharma behemoths and the success of the eDNA platform, as well as the development of ctLNP for the delivery of large genes without an immune response.

Assessing real business returns is critical for capital protection amid volatility. This indicator aggregates net income over the last four quarters, allocating it per share to determine the fundamental value of a stake. By analyzing the EPS TTM dynamics of Generation Bio Co. (GBIO), an investor can discern the actual financial result stripped of market noise. Negative values here are often driven by high costs associated with the cryogenic transportation of drugs. Expensive specialized logistics directly impact the final profitability of each share.